Kasabach-Merritt Syndrome Workup
- Author: Alexandra C Cheerva, MD, MS; Chief Editor: Hassan M Yaish, MD more...
Any infant with unexplained thrombocytopenia, with or without evidence of disseminated intravascular coagulation (DIC), should be evaluated for visceral or hidden vascular lesions (especially of the spleen). Without prompt and appropriate attention, these forms of Kasabach-Merritt syndrome (KMS) are associated with a high mortality. Patients should also be evaluated for malignancy because malignant lesions may resemble the lesions seen in patients with KMS.
Clinicians must monitor blood work, with special emphasis on the platelet count. Additional tests are ordered as necessary for clinical evaluation. For example, blood cultures may be appropriate for excluding the possibility of sepsis, and chromosome tests may be needed to exclude certain genetic syndromes.
Diagnostic imaging is obtained as appropriate. No procedures are required initially. If a complete excision is not feasible, a biopsy should not be performed, because it may lead to uncontrolled bleeding at the site.
Although formal staging is not usually performed, documenting the extent of the invasion of the vascular lesion into normal tissue is important for possible subsequent treatment with surgery or radiation. Metastasis does not occur.
A complete blood count (CBC) count with differential, reticulocyte count, platelet count, and peripheral smear is obtained to evaluate for microangiopathic hemolytic anemia and thrombocytopenia in KMS. Platelets may be larger than normal when they are released early from the bone marrow. Burr cells and schistocytes may be present in patients with microangiopathic hemolytic anemia.
The prothrombin time (PT) and activated partial thromboplastin time (aPTT) are prolonged in patients with significant DIC.
Fibrinogen levels are low in patients with significant DIC. levels of fibrin degradation products (FDPs) and D-dimer are elevated in patients with DIC. A D-dimer test is usually more sensitive than a test for FDPs. Low-grade chronic DIC may be present.
Radiography, CT, MRI, and Ultrasonography
Radiography, computed tomography (CT), and magnetic resonance imaging (MRI) of areas involved with known vascular lesions should be performed as appropriate. These studies are advisable even when all vascular lesions are cutaneous. Scans are important to determine the extent of the visible vascular lesions and to evaluate the patient for possible visceral vascular lesions.
MRI or CT commonly reveals a vascular enhancing mass that is difficult to differentiate from a vascular malformation, solid tumor, or proliferative vascular lesion. If KMS is suspected in patients who have no visible vascular lesions, CT scans or MRIs of the head, chest, abdomen, and pelvis should be obtained to identify any visceral lesions.
Doppler flow studies may help differentiate a solid mass from a vascular lesion.
Radionuclide imaging may be indicated. Scans that use chromium isotope 51, indium In 111 oxine–labeled platelets, or iodine I 131–labeled fibrinogen probably are more sensitive than CT scans or MRIs for delineating the size and number of vascular lesions. Radionuclide scans are infrequently used because the diagnosis is usually made clinically. In certain centers, they may not be readily available. Scintigraphic studies should be strongly considered when the etiology of the thrombocytopenia remains uncertain.
Enjolras et al characterized the histology of kaposiform hemangioendothelioma (KHE) and tufted angioma (TA), the vascular lesions associated with KMS. The original case report described lobules of fine capillaries separated by cellular intercapillary tissue consisting of spindle-shaped cells.
The histologic picture of KHE consists of lobules or sheets of tightly packed spindle cells or rounded endothelial cells and pericytes. The cellular areas have an infiltrative pattern in the dermis, subcutaneous fat, and muscles and generally contain few obvious vascular lumina. TAs are composed of small tufts or lobules of rounded capillaries with small lumina. The tufts are discrete and evenly distributed in a cannonball pattern and are characterized by peripheral, crescentic, slitlike vessels and an associated fibrosis.
Both KHE and TA contain aggregates of rounded, dilated capillaries lined by attenuated endothelial cells with small, dark nuclei and filled with RBCs. Microthrombi and hemosiderin deposits are often present. Lymphlike vessels are often part of the lesion. Findings of both KHE and TA often appear in the same patient; the 2 conditions may be variations of each another.
The histology of classic hemangioma of infancy, which is the most common benign vascular neoplasm in children, is distinct from these proliferations and is not associated with KMS.
Kasabach HH, Merritt KK. Capillary hemangioma with extensive purpura: report of a case. Am J Dis Child. 1940. 59:1063-70.
Kelly M. Kasabach-Merritt phenomenon. Pediatr Clin North Am. 2010 Oct. 57(5):1085-9. [Medline].
Hatley RM, Sabio H, Howell CG, Flickinger F, Parrish RA. Successful management of an infant with a giant hemangioma of the retroperitoneum and Kasabach-Merritt syndrome with alpha-interferon. J Pediatr Surg. 1993 Oct. 28(10):1356-7; discussion 1358-9. [Medline].
Martin MC, Harrington H, Wong WW. Massive congenital kaposiform hemangioendothelioma of the eyelid in a neonate. J Craniofac Surg. 2011 Nov. 22(6):e38-41. [Medline].
Enjolras O, Wassef M, Mazoyer E, et al. Infants with Kasabach-Merritt syndrome do not have "true" hemangiomas. J Pediatr. 1997 Apr. 130(4):631-40. [Medline].
Szlachetka DM. Kasabach-Merritt syndrome: a case review. Neonatal Netw. 1998 Feb. 17(1):7-15. [Medline].
Payne LG, Hayward CPM, Kelton JG. Destruction of red cells by the vasculature and reticuloendothelial system. Hematology of Infancy and Childhood. 1998. 523-43.
Berman B, Lim H. Concurrent cutaneous and hepatic hemangiomata in infancy: report of a case and a review of the literature. J Dermatol Surg Oncol. 1978 Nov. 4(11):869-73. [Medline].
Ram SP. Kasabach-Merritt syndrome and Down's syndrome. J R Soc Med. 1997 Mar. 90(3):159-60. [Medline].
Enjolras O, Riche MC, Merland JJ, Escande JP. Management of alarming hemangiomas in infancy: a review of 25 cases. Pediatrics. 1990 Apr. 85(4):491-8. [Medline].
Tang JY, Chen J, Pan C, Yin MZ, Zhu M. Diffuse cavernous hemangioma of the spleen with Kasabach-Merritt syndrome misdiagnosed as idiopathic thrombocytopenia in a child. World J Pediatr. 2008 Aug. 4(3):227-30. [Medline].
Mitsuhashi N, Furuta M, Sakurai H, et al. Outcome of radiation therapy for patients with Kasabach-Merritt syndrome. Int J Radiat Oncol Biol Phys. 1997 Sep 1. 39(2):467-73. [Medline].
Pampin C, Devillers A, Treguier C, et al. Intratumoral consumption of indium-111-labeled platelets in a child with splenic hemangioma and thrombocytopenia. J Pediatr Hematol Oncol. 2000 May-Jun. 22(3):256-8. [Medline].
Sadan N, Wolach B. Treatment of hemangiomas of infants with high doses of prednisone. J Pediatr. 1996 Jan. 128(1):141-6. [Medline].
Nako Y, Fukushima N, Igarashi T, Hoshino M, Sugiyama M, Tomomasa T, et al. Successful interferon therapy in a neonate with life-threatening Kasabach-Merritt syndrome. J Perinatol. 1997 May-Jun. 17(3):244-7. [Medline].
Hu B, Lachman R, Phillips J, et al. Kasabach-Merritt syndrome-associated kaposiform hemangioendothelioma successfully treated with cyclophosphamide, vincristine, and actinomycin D. J Pediatr Hematol Oncol. 1998 Nov-Dec. 20(6):567-9. [Medline].
Wananukul S, Nuchprayoon I, Seksarn P. Treatment of Kasabach-Merritt syndrome: a stepwise regimen of prednisolone, dipyridamole, and interferon. Int J Dermatol. 2003 Sep. 42(9):741-8. [Medline].
Drucker AM, Pope E, Mahant S, Weinstein M. Vincristine and corticosteroids as first-line treatment of Kasabach-Merritt syndrome in kaposiform hemangioendothelioma. J Cutan Med Surg. 2009 May-Jun. 13(3):155-9. [Medline].
López V, Martí N, Pereda C, Martín JM, Ramón D, Mayordomo E, et al. Successful management of Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon using vincristine and ticlopidine. Pediatr Dermatol. 2009 May-Jun. 26(3):365-6. [Medline].
Hara K, Yoshida T, Kajiume T, Ohno N, Kawaguchi H, Kobayashi M. Successful treatment of Kasabach-Merritt syndrome with vincristine and diagnosis of the hemangioma using three-dimensional imaging. Pediatr Hematol Oncol. 2009 Jul-Aug. 26(5):375-80. [Medline].
Hartman KR, Moncur JT, Minniti CP, Creamer KM. Mediastinal Kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon in an infant: treatment with interferon. J Pediatr Hematol Oncol. 2009 Sep. 31(9):690-2. [Medline].
Yoon HS, Lee JH, Moon HN, Seo JJ, Im HJ, Goo HW. Successful treatment of retroperitoneal infantile hemangioendothelioma with Kasabach-Merritt syndrome using steroid, alpha-interferon, and vincristine. J Pediatr Hematol Oncol. 2009 Dec. 31(12):952-4. [Medline].
Blei F, Karp N, Rofsky N, Rosen R, Greco MA. Successful multimodal therapy for kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon: case report and review of the literature. Pediatr Hematol Oncol. 1998 Jul-Aug. 15(4):295-305. [Medline].
Leong E, Bydder S. Use of radiotherapy to treat life-threatening Kasabach-Merritt syndrome. J Med Imaging Radiat Oncol. 2009 Feb. 53(1):87-91. [Medline].
Argenta LC, Bishop E, Cho KJ, et al. Complete resolution of life-threatening hemangioma by embolization and corticosteroids. Plast Reconstr Surg. 1982 Dec. 70(6):739-44. [Medline].
Stanley P, Gomperts E, Woolley MM. Kasabach-Merritt syndrome treated by therapeutic embolization with polyvinyl alcohol. Am J Pediatr Hematol Oncol. 1986 Winter. 8(4):308-11. [Medline].
Jiang RS, Hu R. Successful treatment of Kasabach-Merritt syndrome arising from kaposiform hemangioendothelioma by systemic corticosteroid therapy and surgery. Int J Clin Oncol. 2012 Oct. 17(5):512-6. [Medline].
Akyuz C, Emir S, Buyukpamukcu M, et al. Successful treatment with interferon alfa in infiltrating angiolipoma: a case presenting with Kasabach-Merritt syndrome. Arch Dis Child. 2003 Jan. 88(1):67-8. [Medline]. [Full Text].
Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med. 1992 May 28. 326(22):1456-63. [Medline].
Michaud AP, Bauman NM, Burke DK, et al. Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope. 2004 Jul. 114(7):1231-6. [Medline].
de la Hunt MN. Kasabach-Merritt syndrome: dangers of interferon and successful treatment with pentoxifylline. J Pediatr Surg. 2006 Jan. 41(1):e29-31. [Medline].
Haisley-Royster C, Enjolras O, Frieden IJ, et al. Kasabach-merritt phenomenon: a retrospective study of treatment with vincristine. J Pediatr Hematol Oncol. 2002 Aug-Sep. 24(6):459-62. [Medline].
Hurvitz SA, Hurvitz CH, Sloninsky L, Sanford MC. Successful treatment with cyclophosphamide of life-threatening diffuse hemangiomatosis involving the liver. J Pediatr Hematol Oncol. 2000 Nov-Dec. 22(6):527-32. [Medline].
Perez Payarols J, Pardo Masferrer J, Gomez Bellvert C. Treatment of life-threatening infantile hemangiomas with vincristine. N Engl J Med. 1995 Jul 6. 333(1):69. [Medline].
Fernandez-Pineda I, Lopez-Gutierrez JC, Ramirez G, Marquez C. Vincristine-ticlopidine-aspirin: an effective therapy in children with Kasabach-Merritt phenomenon associated with vascular tumors. Pediatr Hematol Oncol. 2010 Nov. 27(8):641-5. [Medline].
Traivaree C, Lumkul R, Torcharus K, Krutuecho T, Sriphaisal T. Outcome of Kasabach-Merritt phenomenon: the role of vincristine as monotherapy: report of a case. J Med Assoc Thai. 2012 May. 95 Suppl 5:S181-5. [Medline].
Fuchimoto Y, Morikawa N, Kuroda T, Hirobe S, Kamagata S, Kumagai M, et al. Vincristine, actinomycin D, cyclophosphamide chemotherapy resolves Kasabach-Merritt syndrome resistant to conventional therapies. Pediatr Int. 2012 Apr. 54(2):285-7. [Medline].
Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008 Jun 12. 358(24):2649-51. [Medline].
Su L, Wang D, Fan X. Comprehensive therapy for hemangioma presenting with Kasabach-Merritt syndrome in the maxillofacial region. J Oral Maxillofac Surg. 2015 Jan. 73 (1):92-8. [Medline].
George M, Singhal V, Sharma V, Nopper AJ. Successful surgical excision of a complex vascular lesion in an infant with Kasabach-Merritt syndrome. Pediatr Dermatol. 2002 Jul-Aug. 19(4):340-4. [Medline].
Yang YH, Lee PI, Lin KH, Tsang YM. Absolute ethanol embolotherapy for hemangioma with Kasabach-Merritt syndrome. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1998 Jan-Feb. 39(1):51-4. [Medline].
Hosono S, Ohno T, Kimoto H, Nagoshi R, Shimizu M, Nozawa M, et al. Successful transcutaneous arterial embolization of a giant hemangioma associated with high-output cardiac failure and Kasabach-Merritt syndrome in a neonate: a case report. J Perinat Med. 1999. 27(5):399-403. [Medline].
Komiyama M, Nakajima H, Kitano S, Sakamoto H, Kurimasa H, Ozaki H. Endovascular treatment of huge cervicofacial hemangioma complicated by Kasabach-Merritt syndrome. Pediatr Neurosurg. 2000 Jul. 33(1):26-30. [Medline].
Wolfe SQ, Farhat H, Elhammady MS, Moftakhar R, Aziz-Sultan MA. Transarterial embolization of a scalp hemangioma presenting with Kasabach-Merritt syndrome. J Neurosurg Pediatr. 2009 Nov. 4(5):453-7. [Medline].
Enomoto Y, Yoshimura S, Egashira Y, Iwama T. Transarterial embolization for cervical hemangioma associated with Kasabach-merritt syndrome. Neurol Med Chir (Tokyo). 2011. 51(5):375-8. [Medline].
Poetke M, Philipp C, Berlien HP. Flashlamp-pumped pulsed dye laser for hemangiomas in infancy: treatment of superficial vs mixed hemangiomas. Arch Dermatol. 2000 May. 136(5):628-32. [Medline].
Aylett SE, Williams AF, Bevan DH, Holmes SJ. The Kasabach-Merritt syndrome: treatment with intermittent pneumatic compression. Arch Dis Child. 1990 Jul. 65(7):790-1. [Medline].
Schild SE, Buskirk SJ, Frick LM, Cupps RE. Radiotherapy for large symptomatic hemangiomas. Int J Radiat Oncol Biol Phys. 1991 Aug. 21(3):729-35. [Medline].
Hesselmann S, Micke O, Marquardt T, et al. Case report: Kasabach-Merritt syndrome: a review of the therapeutic options and a case report of successful treatment with radiotherapy and interferon alpha. Br J Radiol. 2002 Feb. 75(890):180-4. [Medline].